Revascular Bio has received an investment of 220 million JPY from Osaka University Venture Capital Co., Ltd. Based on the funds raised this time, we will establish a method for preparing vascular endothelial stem cells and transfer the technology to a cell culture processing facility to realize cell therapy for intractable skin ulcers.

Read More Here:  https://blog.ouvc.co.jp/en/topics/231110-0

Our President and CEO, Kazuo Omori, has been chosen to participate in the Berkeley Skydeck, a globally recognized startup accelerator program affiliated with the University of California, Berkeley. We are proud to announce our selection as a presenter for the final pitch competition.

Through this program, we aspire to expedite the development of our network and the expansion of our business in both the U.S. and global markets.